Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users;Impacto na função renal de uma dose de reforço de rosuvastatina prévia a intervenção coronária percutânea eletiva nos pacientes em uso crônico de estatina

Revista Brasileira de Cardiologia Invasiva

Volumn 20, Issue 3, 2012, Pages 303-308

  de Oliveira, Mauricio Sales ^a   Martins, Kleber Bomfim Araujo ^b   Costa, J Ribamar ^a   Abizaid, Alexandre ^a   Stadler, Jackson ^a   Mattos, Luiz Alberto ^a   Chamié, Daniel ^a   Siqueira, Dimytri ^a   Costa, Ricardo ^a   Staico, Rodolfo ^a   Feres, Fausto ^a   Sousa, Amanda G M R ^a   Sousa, J Eduardo ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b Médico cardiologista intervencionista do Hospital São Lucas   (Brazil)

Author keywords

Angioplasty; Contrast media; Creatinine; Kidney diseases; Statins

Indexed keywords

ROSUVASTATIN;

ADULT; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84872060934     PISSN: 01041843     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0104-1843(12)50051-2     Document Type: Article

References (12)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930-6.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419-28.
3. McCullough PA, Adam A, Becker CR, Davidson C, LameireN, Stacul F, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006; 98(6A):5K-13K.
4. Zhang T, Shen LH, Hu LH, He B. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol. 2011;33(4):344-51.
5. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-64.
6. Sudarsky D, Nikolsky E. Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovasc Dis. 2011; 4:85-99.
7. Farmer JA. Pleiotropic effects of statins. Curr Atheroscler Rep. 2000;2(3):208-17.
8. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. Am J Cardiol. 2011;108(1):1-7.
9. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115(25):3189-96.
10. Wassmann S, Faul A, Hennen B, Scheller B, Böhm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003;93(9):e98-103.
11. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol. 2011;27(6):851-8.
12. Guitterez NV, Diaz A, Timmis GC, O'Neill WW, Stevens MA, Sandberg KR, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol. 2002; 15(5):349-54.